Registration is now open - confirm your place online
Free registration for in-house IP/patent counsel, general counsel and heads of legal Law firms, IP service providers and consultancies save $300 before August 2
Managing IP is excited to announce the return of the fourth annual MIP Life Sciences Forum 2019 taking place at the Convene 810 Seventh Ave, New York on September 18 .This one day forum will address the latest decisions and tumultuous changes affecting the life sciences industry today.While AbbVie Inc. and Boehringer Ingelheim GmbH may have settled their biosimilar dispute in relation to Humira, the FDA's recent approval of Samsung Bioepis's biosimilar was at the same time followed by the almost immediate launch of litigation by Amgen in responseThese two cases represent how difficult and complex the curent landscape for patent prosecution and litigation is right now in the biosimilars markets and beyond. While the threats are huge, the opportunities have never been greater for those get their patent prosecution, protection, litigation, and commercialization strategies right.By attending, you will be able to benchmark your practices against those of your peers, and understand what you need to do to take advantage of the considerable opportunities available, while at the same time protecting your patents and minimising your risk. Download brochure Benefits of attending
Who will you meet?
REGISTRATION & MARKETING QUERIES Kevin Pragas email@example.com +44 207 779 8938 SPEAKING QUERIES Raf O'Reilly firstname.lastname@example.org SPONSORSHIP QUERIES: Melanie Petch email@example.com +44 207 779 8836
July /August 2019
AI and IP: the view from above
Managing IP speaks to the directors of WIPO and the EUIPO to gauge their views on AI, asking how the technology can help the offices be more efficient and whether job losses are inevitable
The material on this site is for financial institutions, professional investors
and their professional advisers. It is for information only. Please read our
Terms and Conditions
before using the site. All material subject to strictly enforced copyright laws.
© 2019 Euromoney Institutional Investor PLC. For help please
see our FAQ.
Switching to MIP International